Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021)
Janux Therapeutics (JANX) reported Long-Term Debt Issuances of $68.8 million for Q2 2021, up 22.9% quarter-over-quarter from $56.0 million in Q1 2021.
Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Janux Therapeutics (JANX) has 2 years of Long-Term Debt Issuances data on file, last reported at $68.8 million in Q2 2021.
- Long-Term Debt Issuances for Q2 2021 came in at $68.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $68.8 million (changed N/A YoY), and the FY2021 annual result was $124.8 million, up 1294.07% from the prior year.
- Long-Term Debt Issuances advanced to $68.8 million in Q2 2021 per JANX's latest filing, from $56.0 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $68.8 million in Q2 2021 and troughed at -$4.5 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 68.83 Mn |
| Jun 30, 2021 | 68.83 Mn |
| Mar 31, 2021 | 56.00 Mn |
| Mar 31, 2021 | 56.00 Mn |
| Dec 31, 2020 | 8.95 Mn |
| Dec 31, 2020 | 8.95 Mn |
| Sep 30, 2020 | -4.50 Mn |
| Sep 30, 2020 | -4.50 Mn |